Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

• Published in: Neurologia medico-chirurgica Vol. 58; no. 10; pp. 405 - 421
• Main Authors: TANAKA, Shingo, NAKADA, Mitsutoshi, FURUTA, Takuya, JIAPAER, Shabierjiang, KITABAYASHI, Tomohiro
• Format: Journal Article
• Language: English
• Published: Japan The Japan Neurosurgical Society 2018; THE JAPAN NEUROSURGICAL SOCIETY; Japan Science and Technology Agency
• Subjects: Antineoplastic Agents, Alkylating - therapeutic use; Autophagy; Brain cancer; Brain Neoplasms - drug therapy; Brain tumors; Cell self-renewal; chemosensitivity; Chemotherapy; Cytotoxicity; DNA methyltransferase; Drug resistance; Drug Resistance, Neoplasm; Glioblastoma; Glioblastoma - drug therapy; glioma; Humans; Immunotherapy; Methylguanine; miRNA; Mismatch repair; O6-methylguanine-DNA methyltransferase; Phagocytosis; Review; Stem cells; Surgery; Temozolomide; Temozolomide - therapeutic use; Therapeutic applications; Tumor cells; temozolomide; chemosensitivity; glioma

Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality rate. Although the current standard therapy consists of surgery followed by radiation and temozolomide (TMZ), chemotherapy can extend patient’s post-operative survival but most cases eventually demonstrate res...